<DOC>
	<DOCNO>NCT00475215</DOCNO>
	<brief_summary>The purpose trial research safety show fast recovery administration 2.0 mg/kg 4.0 mg/kg Org 25969 ( sugammadex ) give reversal agent ZemuronÂ® subject diagnose history pulmonary disease .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Org 25969 Subjects With Having Past History Pulmonary Disease ( 19.4.308 ) ( P05932 )</brief_title>
	<detailed_description />
	<criteria>ASA Class 2 3 ; 18 year age old ; Diagnosed past history pulmonary disease ; Scheduled elective surgical procedure general anesthesia require neuromuscular block use rocuronium ; Scheduled surgery supine position ; Given write informed consent ; Subjects difficult intubation expect due anatomical malformation ; Subjects know suspect neuromuscular disorder impair neuromuscular blockade and/or significant renal dysfunction ; Subjects know suspect ( family ) history malignant hyperthermia ; Subjects know suspect allergy narcotic , muscle relaxant medication use surgery ; Subjects receive medication know interfere neuromuscular block agent anticonvulsant , antibiotic Mg2+ ; Female subject pregnant breastfeeding ; Females subject childbearing potential use acceptable method birth control [ condom diaphragm spermicide , vasectomized partner ( &gt; 6 month ) , IUD , abstinence ] use hormonal contraception birth control ; Subjects already participate Org 25969 trial include Protocol 19.4.308 ; Subjects participate another clinical trial , preapproved Organon , within 30 day enter Protocol 19.4.308 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>